All News

1 February 2008

New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque PsoriasisAntibodies

31 January 2008

TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease PatientsAntibodies

31 January 2008

Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in the LancetAntibodies

29 January 2008

Viventia Biotech To Explore Strategic AlternativesAntibodies

29 January 2008

Abbott and Eisai Finalize License Agreement in Japan for Additional Indications for Adalimumab, The Only Fully Human Monoclonal anti-TNFalpha AntibodyAntibodies

28 January 2008

Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell ProgramAntibodies

28 January 2008

Lpath Successfully Humanizes Breakthrough Anti-LPA Antibody, Lpathomab(TM)Antibodies

28 January 2008

Abbott and Eisai Announce Changes in the Sales Scheme in Japan for Adalimumab, A Fully Human Monoclonal Anti-TNF-alpha AntibodyAntibodies

28 January 2008

Avastin receives broad label extension in Europe for the treatment of patients with metastatic colorectal cancerAntibodies

25 January 2008

MabThera increases the time patients with the most common form of adult leukaemia live without their cancer progressingAntibodies

25 January 2008

MabThera meets study primary endpoint in improving disease symptoms when used as first biologic therapy in patients with rheumatoid arthritisAntibodies

24 January 2008

KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer PatientsAntibodies

24 January 2008

Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))Antibodies

22 January 2008

CytoFab(TM) phase 2 programme in severe sepsis commenced byAstraZenecaAntibodies

22 January 2008

Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung CancerAntibodies

18 January 2008

ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of CancerAntibodies

16 January 2008

MorphoSys Discloses GM-CSF as Target of MOR103 ProgramAntibodies

16 January 2008

New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and AdolescentsAntibodies

15 January 2008

ZymoGenetics Announces Special Protocol Assessment for Atacicept in General SLEAntibodies

15 January 2008

Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus ErythematosusAntibodies

15 January 2008

Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody TherapyAntibodies

15 January 2008

BioInvent and Genentech Initiate Phase I Clinical Trial for BI-204, a potential treatment for cardiovascular conditions associated with atherosclerosisAntibodies

14 January 2008

FDA Approves TYSABRI(R) For The Treatment Of Moderate-To-Severe Crohn’s DiseaseAntibodies

9 January 2008

TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric AntibodyAntibodies

8 January 2008

Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune DiseasesAntibodies

8 January 2008

Medarex Announces Allowance of Investigational New Drug Application for Wholly Owned Fully Human Anti-CD70 Antibody, MDX-1411Antibodies

8 January 2008

Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to OphthotechAntibodies

7 January 2008

Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin LymphomaAntibodies

4 January 2008

Genmab Announces HuMax-CD32B Pre-Clinical ProgramAntibodies

3 January 2008

Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against RabiesAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TROP-2-Targeted Immunotherapy Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

CD40 Agonists & CD40/L Antagonists Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Mesothelin-Targeted Immunotherapy Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review